{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T05:01:56Z","timestamp":1794632516414,"version":"4.9.1"},"reference-count":47,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T00:00:00Z","timestamp":1757721600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82171178"],"award-info":[{"award-number":["82171178"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.neurot.2025.e00756","type":"journal-article","created":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T05:43:26Z","timestamp":1758951806000},"page":"e00756","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Metabolomics and lipidomics study on serum metabolite signatures in Alzheimer's disease and mild cognitive impairment"],"prefix":"10.1016","volume":"22","author":[{"given":"Yingren","family":"Mai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengjie","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyan","family":"Mi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyu","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiqi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kejun","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoxiang","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wang","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neurot.2025.e00756_bib1","doi-asserted-by":"crossref","first-page":"418","DOI":"10.3389\/fnagi.2018.00418","article-title":"Nitrendipine and dementia: forgotten positive facts?","volume":"10","author":"Novotny","year":"2018","journal-title":"Front Aging Neurosci"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00756_bib2","doi-asserted-by":"crossref","first-page":"313","DOI":"10.14283\/jpad.2021.15","article-title":"The epidemiology of Alzheimer's Disease modifiable risk factors and prevention","volume":"8","author":"Zhang","year":"2021","journal-title":"The journal of prevention of Alzheimer's disease"},{"issue":"5","key":"10.1016\/j.neurot.2025.e00756_bib3","doi-asserted-by":"crossref","first-page":"3708","DOI":"10.1002\/alz.13809","article-title":"2024 Alzheimer's disease facts and figures","volume":"20","year":"2024","journal-title":"Alzheimer's & Dementia : the journal of the Alzheimer's Association"},{"issue":"10284","key":"10.1016\/j.neurot.2025.e00756_bib4","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/S0140-6736(20)32205-4","article-title":"Alzheimer's disease","volume":"397","author":"Scheltens","year":"2021","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.neurot.2025.e00756_bib5","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.14506.1","article-title":"Current understanding of Alzheimer's disease diagnosis and treatment","volume":"7","author":"Weller","year":"2018","journal-title":"F1000Research"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00756_bib6","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/S1474-4422(20)30440-3","article-title":"New insights into atypical Alzheimer's disease in the era of biomarkers","volume":"20","author":"Graff-Radford","year":"2021","journal-title":"Lancet Neurol"},{"issue":"2 Dementia","key":"10.1016\/j.neurot.2025.e00756_bib7","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1212\/CON.0000000000000313","article-title":"Mild cognitive impairment","volume":"22","author":"Petersen","year":"2016","journal-title":"Continuum"},{"issue":"1804","key":"10.1016\/j.neurot.2025.e00756_bib8","first-page":"17","article-title":"Diagnosing and managing mild cognitive impairment","volume":"261","author":"Behrman","year":"2017","journal-title":"Practitioner"},{"issue":"6","key":"10.1016\/j.neurot.2025.e00756_bib9","doi-asserted-by":"crossref","first-page":"427","DOI":"10.7326\/0003-4819-148-6-200803180-00005","article-title":"Prevalence of cognitive impairment without dementia in the United States","volume":"148","author":"Plassman","year":"2008","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00756_bib10","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abb5398","article-title":"Molecular subtyping of Alzheimer's disease using RNA sequencing data reveals novel mechanisms and targets","volume":"7","author":"Neff","year":"2021","journal-title":"Sci Adv"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00756_bib11","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1080\/17460441.2020.1674808","article-title":"Recent advances from metabolomics and lipidomics application in Alzheimer'S disease inspiring drug discovery","volume":"15","author":"Cuperlovic-Culf","year":"2020","journal-title":"Expet Opin Drug Discov"},{"key":"10.1016\/j.neurot.2025.e00756_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2023.101987","article-title":"Integrative metabolomics science in Alzheimer's disease: relevance and future perspectives","volume":"89","author":"Lista","year":"2023","journal-title":"Ageing Res Rev"},{"issue":"14","key":"10.1016\/j.neurot.2025.e00756_bib13","doi-asserted-by":"crossref","first-page":"5709","DOI":"10.1021\/acs.analchem.0c04686","article-title":"A metabolite array technology for precision medicine","volume":"93","author":"Xie","year":"2021","journal-title":"Anal Chem"},{"issue":"6","key":"10.1016\/j.neurot.2025.e00756_bib14","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1038\/nprot.2011.319","article-title":"Web-based inference of biological patterns, functions and pathways from metabolomic data using MetaboAnalyst","volume":"6","author":"Xia","year":"2011","journal-title":"Nat Protoc"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00756_bib15","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"2018","journal-title":"J Roy Stat Soc B"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00756_bib16","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1159\/000466688","article-title":"Serum amino acid profiles in normal subjects and in patients with or at risk of alzheimer dementia","volume":"7","author":"Corso","year":"2017","journal-title":"Dement Geriatr Cogn Dis Extra"},{"key":"10.1016\/j.neurot.2025.e00756_bib17","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jpba.2014.10.010","article-title":"Metabolite profiling for the identification of altered metabolic pathways in Alzheimer's disease","volume":"107","author":"Gonz\u00e1lez-Dom\u00ednguez","year":"2015","journal-title":"J Pharmaceut Biomed Anal"},{"issue":"12","key":"10.1016\/j.neurot.2025.e00756_bib18","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.clinbiochem.2010.04.072","article-title":"Plasma metabolic profiling of Alzheimer's disease by liquid chromatography\/mass spectrometry","volume":"43","author":"Li","year":"2010","journal-title":"Clin Biochem"},{"issue":"10","key":"10.1016\/j.neurot.2025.e00756_bib19","doi-asserted-by":"crossref","DOI":"10.3390\/metabo12100949","article-title":"Multi-Omics, an integrated approach to identify novel blood biomarkers of Alzheimer's Disease","volume":"12","author":"Fran\u00e7ois","year":"2022","journal-title":"Metabolites"},{"issue":"21","key":"10.1016\/j.neurot.2025.e00756_bib20","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222111677","article-title":"Glutamate and GABA in Microglia-Neuron cross-talk in Alzheimer's Disease","volume":"22","author":"Czapski","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.neurot.2025.e00756_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.pneurobio.2022.102331","article-title":"Astrocyte energy and neurotransmitter metabolism in Alzheimer's disease: integration of the glutamate\/GABA-glutamine cycle","volume":"217","author":"Andersen","year":"2022","journal-title":"Prog Neurobiol"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00756_bib22","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jalz.2018.07.217","article-title":"Altered bile acid profile associates with cognitive impairment in Alzheimer's disease-An emerging role for gut microbiome","volume":"15","author":"MahmoudianDehkordi","year":"2019","journal-title":"Alzheimer's Dementia: J Alzheimer's Assoc"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00756_bib23","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.jalz.2018.08.012","article-title":"Altered bile acid profile in mild cognitive impairment and Alzheimer's disease: relationship to neuroimaging and CSF biomarkers","volume":"15","author":"Nho","year":"2019","journal-title":"Alzheimer's Dementia: J Alzheimer's Assoc"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00756_bib24","doi-asserted-by":"crossref","first-page":"8709","DOI":"10.1038\/s41598-024-58725-0","article-title":"Extensive targeted metabolomics analysis reveals the identification of major metabolites, antioxidants, and disease-resistant active pharmaceutical components in Camellia tuberculata (Camellia L.) seeds","volume":"14","author":"Ran","year":"2024","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00756_bib25","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1002\/med.21653","article-title":"Expert insights: the potential role of the gut microbiome-bile acid-brain axis in the development and progression of Alzheimer's disease and hepatic encephalopathy","volume":"40","author":"Jia","year":"2020","journal-title":"Med Res Rev"},{"issue":"5","key":"10.1016\/j.neurot.2025.e00756_bib26","article-title":"Increased intestinal bile acid absorption contributes to age-related cognitive impairment","volume":"5","author":"Ren","year":"2024","journal-title":"Cell Rep Med"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00756_bib27","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1080\/09540260600583007","article-title":"Lipids and the pathogenesis of Alzheimer's disease: is there a link?","volume":"18","author":"Mielke","year":"2006","journal-title":"Int Rev Psychiatr"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00756_bib28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002482","article-title":"Brain and blood metabolite signatures of pathology and progression in Alzheimer disease: a targeted metabolomics study","volume":"15","author":"Varma","year":"2018","journal-title":"PLoS Med"},{"issue":"12","key":"10.1016\/j.neurot.2025.e00756_bib29","doi-asserted-by":"crossref","first-page":"e57","DOI":"10.1038\/tp.2011.55","article-title":"Metabolome in progression to Alzheimer's disease","volume":"1","author":"Ore\u0161i\u010d","year":"2011","journal-title":"Transl Psychiatry"},{"key":"10.1016\/j.neurot.2025.e00756_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.exger.2021.111264","article-title":"Plasma phosphatidylcholines and vitamin B12\/folate levels are possible prognostic biomarkers for progression of Alzheimer's disease","volume":"147","author":"Blasko","year":"2021","journal-title":"Exp Gerontol"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00756_bib31","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.neurobiolaging.2013.08.001","article-title":"Evidence of altered phosphatidylcholine metabolism in Alzheimer's disease","volume":"35","author":"Whiley","year":"2014","journal-title":"Neurobiol Aging"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00756_bib32","first-page":"154","article-title":"Wide-ranging alterations in the brain fatty acid complement of subjects with late Alzheimer's disease as detected by GC-MS","volume":"8","author":"Nasaruddin","year":"2016","journal-title":"Am J Tourism Res"},{"key":"10.1016\/j.neurot.2025.e00756_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2020.101043","article-title":"Blood fatty acids in Alzheimer's disease and mild cognitive impairment: a meta-analysis and systematic review","volume":"60","author":"Hosseini","year":"2020","journal-title":"Ageing Res Rev"},{"issue":"6","key":"10.1016\/j.neurot.2025.e00756_bib34","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.jalz.2017.11.012","article-title":"Circulating metabolites and general cognitive ability and dementia: evidence from 11 cohort studies","volume":"14","author":"van der Lee","year":"2018","journal-title":"Alzheimer's Dementia : the journal of the Alzheimer's Association"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00756_bib35","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1001\/jamaneurol.2016.4899","article-title":"Association of docosahexaenoic acid supplementation with alzheimer disease stage in apolipoprotein E \u03b54 carriers: a review","volume":"74","author":"Yassine","year":"2017","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurot.2025.e00756_bib36","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.clinbiochem.2019.04.004","article-title":"Blood-based molecular signature of Alzheimer's disease via spectroscopy and metabolomics","volume":"72","author":"Habartov\u00e1","year":"2019","journal-title":"Clin Biochem"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00756_bib37","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.plipres.2009.08.004","article-title":"Acylcarnitines: role in brain","volume":"49","author":"Jones","year":"2010","journal-title":"Prog Lipid Res"},{"issue":"9","key":"10.1016\/j.neurot.2025.e00756_bib38","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1038\/oby.2009.510","article-title":"Increased levels of plasma acylcarnitines in obesity and type 2 diabetes and identification of a marker of glucolipotoxicity","volume":"18","author":"Mihalik","year":"2010","journal-title":"Obesity"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00756_bib39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2337\/db12-0466","article-title":"Acylcarnitines: reflecting or inflicting insulin resistance?","volume":"62","author":"Schooneman","year":"2013","journal-title":"Diabetes"},{"issue":"10","key":"10.1016\/j.neurot.2025.e00756_bib40","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/nrendo.2015.129","article-title":"Acylcarnitines--old actors auditioning for new roles in metabolic physiology","volume":"11","author":"McCoin","year":"2015","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.neurot.2025.e00756_bib41","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.neurobiolaging.2020.04.004","article-title":"Corrigendum to brain and blood metabolome for Alzheimer's dementia: findings from a targeted metabolomics analysis","volume":"91","author":"Huo","year":"2020","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.neurot.2025.e00756_bib42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neurobiolaging.2016.03.005","article-title":"Medium-chain plasma acylcarnitines, ketone levels, cognition, and gray matter volumes in healthy elderly, mildly cognitively impaired, or Alzheimer's disease subjects","volume":"43","author":"Ciavardelli","year":"2016","journal-title":"Neurobiol Aging"},{"issue":"5","key":"10.1016\/j.neurot.2025.e00756_bib43","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0155694","article-title":"Serum levels of acyl-carnitines along the continuum from normal to alzheimer's dementia","volume":"11","author":"Cristofano","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.neurot.2025.e00756_bib44","doi-asserted-by":"crossref","first-page":"719","DOI":"10.3389\/fneur.2017.00719","article-title":"Application of metabolomics in Alzheimer's Disease","volume":"8","author":"Wilkins","year":"2017","journal-title":"Front Neurol"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00756_bib45","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines9030298","article-title":"Mechanistic insights into Alzheimer's Disease unveiled through the investigation of disturbances in central metabolites and metabolic pathways","volume":"9","author":"Gonz\u00e1lez-Dom\u00ednguez","year":"2021","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00756_bib46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s43657-021-00036-9","article-title":"Recent advances in understanding of Alzheimer's Disease progression through Mass spectrometry-based metabolomics","volume":"2","author":"Mill","year":"2022","journal-title":"Phenomics"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00756_bib47","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nm.3466","article-title":"Plasma phospholipids identify antecedent memory impairment in older adults","volume":"20","author":"Mapstone","year":"2014","journal-title":"Nat Med"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187874792500234X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187874792500234X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T16:09:01Z","timestamp":1773158941000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S187874792500234X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":47,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S187874792500234X"],"URL":"https:\/\/doi.org\/10.1016\/j.neurot.2025.e00756","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metabolomics and lipidomics study on serum metabolite signatures in Alzheimer's disease and mild cognitive impairment","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurot.2025.e00756","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of American Society for Experimental NeuroTherapeutics.","name":"copyright","label":"Copyright"}],"article-number":"e00756"}}